JPH09512015A - セルトーリ細胞および同種移植片または異種移植片を用いる疾患処置方法 - Google Patents
セルトーリ細胞および同種移植片または異種移植片を用いる疾患処置方法Info
- Publication number
- JPH09512015A JPH09512015A JP7527083A JP52708395A JPH09512015A JP H09512015 A JPH09512015 A JP H09512015A JP 7527083 A JP7527083 A JP 7527083A JP 52708395 A JP52708395 A JP 52708395A JP H09512015 A JPH09512015 A JP H09512015A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- sertoli
- sertoli cells
- mammal
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/24—Genital tract cells, non-germinal cells from gonads
- C12N2502/246—Cells of the male genital tract, non-germinal testis cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物における生物学的因子の欠損に起因する疾患の処置方法であって 、上記方法は、処置を必要とする哺乳動物にセルトーリ細胞および上記生物学的 因子を産生する細胞の治療的有効量を投与し、上記セルトーリ細胞を免疫学的に 特別免除された部位を創設するに有効な量を投与することを特徴とする方法。 2.上記哺乳動物がヒトである、請求項1記載の方法。 3.上記生物学的因子がホルモンである、請求項1記載の方法。 4.上記生物学的因子がインスリンであり、上記疾患が糖尿病である、請求項 1記載の方法。 5.上記生物学的因子を産生する上記細胞がランゲルハンス膵島細胞である、 請求項4記載の方法。 6.上記生物学的因子を産生する上記細胞が、上記生物学的因子をコードする 核酸によって形質転換された細胞である、請求項1記載の方法。 7.上記投与が移植によるものである、請求項1記載の方法。 8.上記セルトーリ細胞が105〜1010個の細胞の用量で投与される、請求 項1記載の方法。 9.上記生物学的因子を産生する上記細胞が105〜1010個の細胞の用量で 投与される、請求項1記載の方法。 10.上記移植が異種移植によるものである、請求項7記載の方法。 11.上記移植が同種移植によるものである、請求項7記載の方法。 12.さらに、免疫抑制剤の投与を含むものである、請求項1記載の方法。 13.上記免疫抑制剤が上記移植細胞が機能可能になるに十分な期間投与され るものである、請求項12記載の方法。 14.上記免疫抑制剤がシクロスポリンである、請求項12記載の方法。 15.上記シクロスポリンが5〜40mg/kg体重の用量で投与されるものであ る、請求項14記載の方法。 16.さらに、上記生物学的因子を産生する上記細胞の移植後、外来性生物学 的因子の治療的有効量を投与することを含む、請求項1記載の方法。 17.上記生物学的因子を産生する上記細胞が組織培養物中でセルトーリ細胞 とともに共培養される、請求項1記載の方法。 18.上記生物学的因子を産生する細胞が組織培養中にセルトーリ細胞との共 培養前、凍結保存される、請求項17記載の方法。 19.哺乳動物の糖尿病の処置方法であって、上記方法が、糖尿病哺乳動物に 免疫学的に特別免除された部位を創設するのに有効な量のセルトーリ細胞および ランゲルハンス膵島細胞の治療的有効量を投与することを特徴とする方法。 20.上記糖尿病がI型またはII型である、請求項19記載の方法。 21.上記哺乳動物がヒトである、請求項19記載の方法。 22.上記セルトーリ細胞がヒト、ウシまたはブタのものである、請求項19 記載の方法。 23.上記ランゲルハンス膵島細胞がヒト、ウシまたはブタのものである、請 求項19記載の方法。 24.上記投与が移植によるものである、請求項19記載の方法。 25.上記移植が腎嚢下腔への注射によるものである、請求項24記載の方法 。 26.上記移植が皮下筋膜への注射によるものである、請求項24記載の方法 。 27.上記セルトーリ細胞が105〜1010個の細胞の用量で投与される、請 求項19記載の方法。 28.上記ランゲルハンス膵島細胞が5〜1000膵島細胞/g体重の用量で 投与される、請求項19記載の方法。 29.さらに、免疫抑制剤の投与を含むものである、請求項19記載の方法。 30.上記免疫抑制剤が上記移植膵島細胞が機能可能になるに十分な期間投与 されるものである、請求項29記載の方法。 31.上記免疫抑制剤がシクロスポリンである、請求項29記載の方法。 32.上記シクロスポリンが5〜40mg/kg体重の用量で投与されるものであ る、請求項31記載の方法。 33.さらに、上記ランゲルハンス膵島細胞の移植後、インスリンの治療的有 効量を投与することを含む、請求項19記載の方法。 34.哺乳動物に免疫学的に特別免除された部位を創設する方法であって、上 記方法が分離されたセルトーリ細胞を哺乳動物に移植することを含む方法。 35.上記哺乳動物がヒトである、請求項34記載の方法。 36.上記セルトーリ細胞が腎嚢下腔に注射されるものである、請求項34記 載の方法。 37.上記セルトーリ細胞が皮下筋膜に注射されるものである、請求項34記 載の方法。 38.上記セルトーリ細胞が105〜1010個の細胞の用量で移植されるもの である、請求項34記載の方法。 39.上記セルトーリ細胞がヒト、ウシまたはブタのものである、請求項34 記載の方法。 40.エクスビボ細胞の採集および増殖を増強させる方法であって、上記採集 および増殖を増強させるに十分な時間および条件下で、上記細胞とセルトーリ細 胞とを共培養することを特徴とする方法。 41.セルトーリ細胞および生物学的因子を産生する細胞および医薬的に許容 それ得る添加物を含む医薬組成物。 42.上記生物学的因子がホルモンである、請求項41記載の医薬組成物。 43.上記生物学的因子を産生する上記細胞がランゲルハンス膵島細胞である 、請求項41記載の医薬組成物。 44.上記生物学的因子を産生する上記細胞が上記生物学的因子をコードする 核酸によって形質転換された細胞である、請求項41記載の医薬組成物。 45.セルトーリ細胞、ランゲルハンス膵島細胞および医薬的に許容され得る 添加物を含む医薬組成物。 46.セルトーリ細胞および医薬的に許容され得る添加物を含む医薬組成物。 47.セルトーリ細胞を含むのに適した第1の容器、疾患中に欠失または不足 している生物学的因子を産生する細胞を含むのに適した第2の容器を収容するの に適した区画化されたキット。 48.セルトーリ細胞を含むのに適した第1の容器、ランゲルハンス膵島細胞 を含むのに適した第2の容器を収容するのに適した区画化されたキット。 49.包装材料および上記包装材料内に含まれたセルトーリ細胞を含む製品部 材であって、上記セルトーリ細胞が哺乳動物に免疫学的に特別免除された部位を 創設するのに有効であり、上記包装材料は上記セルトーリ細胞が哺乳動物に免疫 学的に特別免除された部位を創設するのに用いられ得ることを示すラベルを含む ことを特徴とする製品部材。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21169594A | 1994-04-13 | 1994-04-13 | |
US08/211,695 | 1994-04-13 | ||
PCT/US1995/004565 WO1995028167A1 (en) | 1994-04-13 | 1995-04-13 | Methods of treating disease using sertoli cells and allografts or xenografts |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09512015A true JPH09512015A (ja) | 1997-12-02 |
Family
ID=22787974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7527083A Pending JPH09512015A (ja) | 1994-04-13 | 1995-04-13 | セルトーリ細胞および同種移植片または異種移植片を用いる疾患処置方法 |
Country Status (12)
Country | Link |
---|---|
US (3) | US5725854A (ja) |
EP (1) | EP0755258B1 (ja) |
JP (1) | JPH09512015A (ja) |
AT (1) | ATE212230T1 (ja) |
AU (1) | AU715177B2 (ja) |
CA (1) | CA2187803C (ja) |
DE (1) | DE69525151T2 (ja) |
DK (1) | DK0755258T3 (ja) |
ES (1) | ES2169128T3 (ja) |
FI (2) | FI120670B (ja) |
NO (1) | NO320713B1 (ja) |
WO (1) | WO1995028167A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010500871A (ja) * | 2006-07-28 | 2010-01-14 | セルトセル・バイオテクノロジー・(ユーエス)・コーポレイション | 成熟セルトリ細胞およびその使用 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ293718B6 (cs) * | 1995-02-08 | 2004-07-14 | Yamanouchi Europe B. V. | Způsob přípravy granulátu obsahujícího orálně účinné beta-laktamové antibiotikum a orální dávkovací forma obsahující orálně účinné beta-laktamové antibiotikum |
WO1996028174A1 (en) * | 1995-03-13 | 1996-09-19 | University Of South Florida | Sertoli cells as transplantation facilitator for cell transplantation |
US5702700A (en) * | 1995-03-13 | 1997-12-30 | University Of South Florida | Sertoli cells as neurorecovery inducing cells for Parkinson's disease |
US5830460A (en) * | 1995-03-13 | 1998-11-03 | University Of South Florida | Sertoli cells as transplantation facilitator for cell transplantation |
AU5390696A (en) * | 1995-04-20 | 1996-11-07 | University Of South Florida | Purified and isolated sertoli cell aggregate |
US6037175A (en) * | 1996-03-12 | 2000-03-14 | The University Of South Florida | Method and media for enhancing cryopreservation of cells |
JP2002500202A (ja) * | 1998-01-02 | 2002-01-08 | タイタン ファーマシューティカルズ, インコーポレイテッド | 免疫優位部位の生成のための色素性網膜上皮細胞の使用 |
ATE452643T1 (de) * | 1998-11-06 | 2010-01-15 | Sertoli Technologies Inc | Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen |
US7399751B2 (en) * | 1999-11-04 | 2008-07-15 | Sertoli Technologies, Inc. | Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells |
CZ302458B6 (cs) * | 1998-12-15 | 2011-06-01 | Universidad Nacional Autonoma De Mexico | Zarízení pro implantaci biologického materiálu |
US6303355B1 (en) | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
US7115256B1 (en) * | 1999-04-09 | 2006-10-03 | Titan Pharmaceuticals, Inc. | Methods of treating schizophrenia |
ATE341335T1 (de) | 2000-01-20 | 2006-10-15 | Diabcell Pty Ltd | Präparation und xenotransplantation von inseln aus schweinen |
US6790441B1 (en) | 2000-06-13 | 2004-09-14 | University Of South Florida | Sertoli cells as biochambers |
AU9118201A (en) | 2000-09-20 | 2002-04-02 | Islet Sheet Medical Llc | Improved methods for fabrication of thin sheet bio-artificial organs |
AU2002305079B8 (en) * | 2001-05-11 | 2006-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Immune modulation device for use in animals |
US20050042746A1 (en) * | 2001-09-28 | 2005-02-24 | Olga Garkavenko | Growing xenotransplant material in culture |
MXPA04008061A (es) * | 2002-02-22 | 2005-06-20 | Prophy Med Ab | Uso de inhibidor o antagonista contra factor tisular. |
US20040062753A1 (en) * | 2002-09-27 | 2004-04-01 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
CN1791670A (zh) * | 2003-06-24 | 2006-06-21 | 戴伯塞尔有限公司 | 用于异种移植的用猪支持细胞培养的猪胰岛 |
US20050118145A1 (en) * | 2003-07-03 | 2005-06-02 | Jannette Dufour | Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants |
WO2006118564A2 (en) * | 2004-04-29 | 2006-11-09 | Washington State University Research Foundation | MODIFIED CELLS EXPRESSING A PROTEIN THAT MODULATES ACTIVITY OF bHLH PROTEINS, AND USES THEREOF |
MX2007001189A (es) | 2004-07-29 | 2008-02-11 | Univ Miami | Dispositivos hibridos para terapias celulares. |
US20070065422A1 (en) * | 2005-09-20 | 2007-03-22 | Cameron Don F | Induction of immune tolerance by sertoli cells |
WO2007089572A2 (en) * | 2006-01-26 | 2007-08-09 | John Constance M | Proliferative primary human sertoli cell cultures and their applications |
WO2009105278A2 (en) | 2008-02-21 | 2009-08-27 | University Of South Florida | Nanoparticle targeted drug delivery to the lungs using extra-testicular sertoli cells |
US8709400B2 (en) * | 2009-07-27 | 2014-04-29 | Washington University | Inducement of organogenetic tolerance for pancreatic xenotransplant |
WO2011025977A2 (en) | 2009-08-28 | 2011-03-03 | Craig Hasilo | Methods and devices for cellular transplantation |
MX2010013135A (es) | 2010-11-30 | 2012-05-31 | Val De Bio S De R L De C V | Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico. |
US10532128B2 (en) | 2015-11-18 | 2020-01-14 | Viera Bioscience, Inc. | Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction |
EP3697469A4 (en) | 2017-10-17 | 2021-09-22 | The Methodist Hospital System | ADMINISTRATION SYSTEMS |
EP3962505A1 (en) | 2019-05-01 | 2022-03-09 | Sernova Corporation | Methods of treating diabetes using devices for cellular transplantation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4829000A (en) * | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
US5158874A (en) * | 1985-08-30 | 1992-10-27 | The United States Of America As Represented By The Department Of Health And Human Services | Determining metastic potential of tumor cells and isolating metastic tumor cells |
US5053332A (en) * | 1989-07-24 | 1991-10-01 | Cook Richard B | Agarose beads, preferably incorporating biological materials |
US5304603A (en) * | 1991-06-18 | 1994-04-19 | The Population Council | Leydig cell stimulator |
DE4227066A1 (de) * | 1992-08-16 | 1994-02-17 | Bernhard Josef Dr Med Hering | Langerhans'sche Inseln in reiner Form |
US5474905A (en) * | 1993-11-24 | 1995-12-12 | Research Corporation Technologies | Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens |
US5849285A (en) * | 1994-04-13 | 1998-12-15 | Research Corporation Technologies, Inc. | Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells |
-
1995
- 1995-04-13 WO PCT/US1995/004565 patent/WO1995028167A1/en active Application Filing
- 1995-04-13 US US08/421,641 patent/US5725854A/en not_active Expired - Lifetime
- 1995-04-13 JP JP7527083A patent/JPH09512015A/ja active Pending
- 1995-04-13 ES ES95916368T patent/ES2169128T3/es not_active Expired - Lifetime
- 1995-04-13 EP EP95916368A patent/EP0755258B1/en not_active Expired - Lifetime
- 1995-04-13 DE DE69525151T patent/DE69525151T2/de not_active Expired - Lifetime
- 1995-04-13 AU AU22893/95A patent/AU715177B2/en not_active Expired
- 1995-04-13 DK DK95916368T patent/DK0755258T3/da active
- 1995-04-13 AT AT95916368T patent/ATE212230T1/de active
- 1995-04-13 CA CA002187803A patent/CA2187803C/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,338 patent/US5759534A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,341 patent/US5843430A/en not_active Expired - Lifetime
-
1996
- 1996-10-08 FI FI964033A patent/FI120670B/fi not_active IP Right Cessation
- 1996-10-11 NO NO19964342A patent/NO320713B1/no not_active IP Right Cessation
-
2008
- 2008-07-18 FI FI20085733A patent/FI120696B/fi not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010500871A (ja) * | 2006-07-28 | 2010-01-14 | セルトセル・バイオテクノロジー・(ユーエス)・コーポレイション | 成熟セルトリ細胞およびその使用 |
JP2014074041A (ja) * | 2006-07-28 | 2014-04-24 | Sertocell Biotechnology (Us) Corp | 成熟セルトリ細胞およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
DK0755258T3 (da) | 2002-05-13 |
DE69525151T2 (de) | 2002-08-14 |
AU715177B2 (en) | 2000-01-20 |
DE69525151D1 (de) | 2002-03-14 |
FI964033A0 (fi) | 1996-10-08 |
CA2187803A1 (en) | 1995-10-26 |
NO320713B1 (no) | 2006-01-23 |
FI20085733A (fi) | 2008-07-18 |
EP0755258B1 (en) | 2002-01-23 |
NO964342L (no) | 1996-12-13 |
US5843430A (en) | 1998-12-01 |
EP0755258A1 (en) | 1997-01-29 |
CA2187803C (en) | 1999-09-28 |
AU2289395A (en) | 1995-11-10 |
NO964342D0 (no) | 1996-10-11 |
FI120670B (fi) | 2010-01-29 |
WO1995028167A1 (en) | 1995-10-26 |
ES2169128T3 (es) | 2002-07-01 |
ATE212230T1 (de) | 2002-02-15 |
FI120696B (fi) | 2010-01-29 |
US5759534A (en) | 1998-06-02 |
FI964033A (fi) | 1996-12-12 |
US5725854A (en) | 1998-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09512015A (ja) | セルトーリ細胞および同種移植片または異種移植片を用いる疾患処置方法 | |
US5849285A (en) | Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells | |
Tzakis et al. | Pancreatic islet transplantation after upper abdominal exeriteration and liver replacement | |
US6149907A (en) | Treatments using sertoli cells | |
DE69535328T2 (de) | In-vitro wachstum von langerhans'schen inseln und ihre verwendungen | |
Ballinger et al. | Transplantation of intact pancreatic islets in rats | |
ES2272482T3 (es) | Preparacion y xenotransplante de islotes porcinos. | |
Tuch et al. | Histologic differentiation of human fetal pancreatic explants transplanted into nude mice | |
US20040082064A1 (en) | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues | |
EP2402019B1 (en) | Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues | |
US6090400A (en) | Pharmaceutical preparation and method for treatment of diabetes | |
JP5579270B2 (ja) | 膵島と脂肪組織由来幹細胞を利用した膵島移植 | |
US20020065212A1 (en) | Methods of treating disease using sertoli cells and allografts or xenografts | |
Korsgren et al. | Porcine islet-like cell clusters cure diabetic nude rats when transplanted under the kidney capsule, but not when implanted into the liver or spleen | |
Inoue et al. | Isolation of adult pig islet: In vitro assessment and xenotransplantation | |
Karl et al. | Transplantation of insulin-secreting tissues. | |
Peterson et al. | Fetal islet transplantation: implications for diabetes | |
OHGAWARA et al. | Monolayer-forming islet cell culture from neonatal pig pancreas: using sequential treatment with EDTA-dispase and monoiodoacetic acid for preparation and purification | |
CA2361563A1 (en) | Use of polyacrylamide gel for forming a connective-tissue capsule in a mammal for cultivating allogenic or xenogenic cells | |
AU8186498A (en) | Treatment for diabetes | |
Sandler et al. | Studies of Fetal Porcine Islet-Like Cell Clusters—A Tissue Source for Xenotransplantation in Insulin-Dependent Diabetes Mellitus? | |
Tuch | O Mouse AA5 A Mouse AA9 25 Mouse W1 20 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031201 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040226 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050118 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050310 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20050324 |